Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect.
Massimo Morfini, Agency for Hemophilia and Regional Reference Center for Inherited Bleeding Disorders, Azienda Ospedalieriero, Universitaria Careggi, Florence, Italy, Tel.: +39 055 7947587, Fax: +39 055 7947794, E-mail: massimo.morfini@unifi.it.
M
M
Morfini
A
A
Batorova
G
G
Mariani
G
G
Auerswald
F
F
Bernardi
G
G
Di Minno
A
A
Dolce
C
C
Fede
M
M
Giansily-Blaizot
J
J
Ingerslev
U
U
Martinowitz
M
M
Napolitano
M
M
Pinotti
J-F
JF
Schved
D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D003029:Coagulants / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016903:Drug Monitoring / Q000379:methods; D005167:Factor VII / Q000235:genetics*; D005168:Factor VII Deficiency / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D015942:Factor VIIa / Q000008:administration & dosage / Q000493:pharmacokinetics*; D020022:Genetic Predisposition to Disease; D040941:Heredity; D006801:Humans; D010641:Phenotype; D011237:Predictive Value of Tests; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics; D012042:Registries; D012720:Severity of Illness Index; D016896:Treatment Outcome
D003029:Coagulants; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa